S&P 500

5.222,68

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Sana Biotechnology Inc (SANA)
Sana Biotechnology Inc (SANA) Notícias

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:SANA

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
08/05/2024	17:49	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:SANA	Sana Biotechnology Inc
08/05/2024	17:21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
08/05/2024	17:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
08/05/2024	17:05	GlobeNewswire Inc.	Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
06/05/2024	17:05	GlobeNewswire Inc.	Sana Biotechnology to Present at May and June 2024 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
08/03/2024	18:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
29/02/2024	18:05	GlobeNewswire Inc.	Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
28/02/2024	18:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference	NASDAQ:SANA	Sana Biotechnology Inc
14/02/2024	18:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
13/02/2024	18:05	GlobeNewswire Inc.	Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP	NASDAQ:SANA	Sana Biotechnology Inc
12/02/2024	18:05	GlobeNewswire Inc.	Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:SANA	Sana Biotechnology Inc
08/02/2024	18:49	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SANA	Sana Biotechnology Inc
08/02/2024	03:22	GlobeNewswire Inc.	Sana Biotechnology Announces Pricing of Upsized Public Offering	NASDAQ:SANA	Sana Biotechnology Inc
07/02/2024	23:59	Edgar (US Regulatory)	Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses	NASDAQ:SANA	Sana Biotechnology Inc
07/02/2024	18:01	GlobeNewswire Inc.	Sana Biotechnology Announces Proposed Public Offering of Common Stock	NASDAQ:SANA	Sana Biotechnology Inc
05/01/2024	11:00	GlobeNewswire Inc.	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies	NASDAQ:SANA	Sana Biotechnology Inc
03/01/2024	18:05	GlobeNewswire Inc.	Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:SANA	Sana Biotechnology Inc
15/12/2023	18:34	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SANA	Sana Biotechnology Inc
11/12/2023	11:00	GlobeNewswire Inc.	Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
01/12/2023	18:05	GlobeNewswire Inc.	Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System	NASDAQ:SANA	Sana Biotechnology Inc
27/11/2023	21:01	PR Newswire (US)	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders	NASDAQ:SANA	Sana Biotechnology Inc
21/11/2023	11:00	GlobeNewswire Inc.	Sana Biotechnology to Present at November and December 2023 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
21/11/2023	08:00	PR Newswire (US)	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics	NASDAQ:SANA	Sana Biotechnology Inc
17/11/2023	11:00	GlobeNewswire Inc.	Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes	NASDAQ:SANA	Sana Biotechnology Inc
09/11/2023	18:05	GlobeNewswire Inc.	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis	NASDAQ:SANA	Sana Biotechnology Inc
08/11/2023	18:05	GlobeNewswire Inc.	Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
02/11/2023	10:05	GlobeNewswire Inc.	Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
01/11/2023	11:30	PR Newswire (US)	Flagship Pioneering Launches Pioneering Intelligence	NASDAQ:SANA	Sana Biotechnology Inc
10/10/2023	17:15	GlobeNewswire Inc.	Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M	NASDAQ:SANA	Sana Biotechnology Inc
11/09/2023	07:30	PR Newswire (US)	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer	NASDAQ:SANA	Sana Biotechnology Inc